Consistently, BLM-SSc mice treated with rmIL-31 showed significantly increased expression of Col1a1, Col1a2, and type I collagen, compared with BLM-SSc mice treated with sham (Fig. 5d, e). The gene discussed is COL1A1; the disease is systemic sclerosis.